Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 153

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 153
---
.A. in Accounting
and Economics from Hebrew University of Jerusalem, and has been a licensed CPA since 2012.

Mr. Jeff Dykan, CPA, Director

Mr. Jeff Dykan has served on our Board of Directors since 2005. He
was appointed by our shareholder SCP Vitalife. Since 2002 Mr. Dykan has been a director of Vitalife Partners Management LP, the general
partner of Vitalife, and since 2007 has been a director of its successor fund, SCP Vitalife GP, the corporate general partner of the common
general partner of SCP Vitalife Partners II L.P. and its affiliate SCP Vitalife Partners (Israel) II L.P. He has also served as a managing
member of SCP Vitalife Management Company, LLC and SCP Vitalife Management Israel Ltd., which by contract provides certain management
services to the common general partner of SCP Vitalife. Prior to joining Vitalife, from 2001 to 2002, Mr. Dykan was the Chairman and Chief
Executive Officer of BitBand Inc., formerly a provider of content management and delivery systems, specializing in video on demand for
IPTV. Mr. Dykan serves currently as Chairman of ReWalk Robotics and was a member of the American Institute of Certified Public Accountants
from 1982 through 2021 and holds a B.Sc. in accounting and management and an M.B.A. in computer applications, both from New York University.

Mr. Keith Valentine, Director

Mr. Keith Valentine has
served on our Board of Directors since 2015. Mr. Valentine has over 30 years of direct spine and orthopedics industry experience. Mr.
Valentine has served as President, Chief Executive Officer and member of the board of directors of Intrinsic Therapeutics, Inc., or Intrinsic
Therapeutics, a medical technology company driving to change the standard of care for lumbar discectomy patients with large annular defects
by reducing reoperations for reherniations, since May 2025. Prior to joining Intrinsic Therapeutics, Mr. Valentine was most recently
President and Chief Executive Officer of Orthofix, Inc. (Nasdaq: OFIX), a global spine and orthopedics company, following its merger
with SeaSpine, Inc., or SeaSpine, in 2023. Prior to the merger in 2023, Mr. Valentine served as Chief Executive Officer and President
of SeaSpine, a global medical technology company focused